Spero Therapeutics shares are trading higher after the company announced a Special Protocol Assessment with the FDA for the Phase 3 PIVOT-PO trial of tebipenem Hbr.
Portfolio Pulse from Benzinga Newsdesk
Spero Therapeutics has announced a Special Protocol Assessment with the FDA for the Phase 3 PIVOT-PO trial of tebipenem Hbr, causing its shares to trade higher.
July 31, 2023 | 4:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Spero Therapeutics' shares are trading higher after the company announced a Special Protocol Assessment with the FDA for the Phase 3 PIVOT-PO trial of tebipenem Hbr.
The announcement of a Special Protocol Assessment with the FDA for the Phase 3 PIVOT-PO trial of tebipenem Hbr is a positive development for Spero Therapeutics. This indicates progress in the company's drug development process, which is likely to be viewed favorably by investors, leading to an increase in the company's share price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100